

AMENDMENTS TO THE SPECIFICATION


On page 16, line 15, following: "CKLLKKLLKLWKKLLKKLKC", please insert: -- (SEQ ID 1) --.

A Replacement Sheet containing the amended paragraph from page 16 of the specification and showing the changes made is attached. The paragraph is found on lines 8-15 of page 16. No new matter is added by this amendment.

Sequence Listing:


The specification has been amended to include a sequence listing for the sequence found in the specification. A sequence listing paper copy has been submitted with this Amendment as an additional sheet to the specification. Please enter the sequence listing paper copy into the specification. A computer readable form has also been submitted. The content of the paper listing and the computer readable form are the same. The sheets do not include new matter.

Respectfully submitted,



\_\_\_\_\_  
Kirk Ekena, Reg. No. 56,672  
Mirus Bio Corporation  
505 South Rosa Road  
Madison, WI 53719  
608-238-4400

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: 9/14/2005.

  
\_\_\_\_\_  
Kirk Ekena



[REPLACEMENT SHEET]

5

Monomers can also be hydrophobic, hydrophilic or amphipathic. Examples of amphipathic compounds include but 10 are not restricted to 3,3'-diamine-N-(7-octene)-N-methyldipropylammonium bromide (Compound 7), N,N'-Dinonacrylate-N,N,N',N'-tetramethylpropanediammonium bromide (Compound 10), N,N',N'',N''-Trinonacrylate-N,N,N',N'',N''-pentamethyldiethylentriammonium bromide (Compound 11) and 15 amphipathic peptides such as CKLLKKLLKLWKKLLKKLKC (SEQ ID 1).